Decent topline growth for Alembic Pharma but margins continue to bother along with one-off expenses due to the acquisition of stake in Aleor Dermaceuticals | Q4 FY22 Result & Earning Call Highlights
Decent topline growth for Alembic Pharma but margins continue to bother along with one-off expenses due to the acquisition of stake in Aleor Dermaceuticals | Q4 FY22 Result & Earning Call Highlights
Decent topline growth for Alembic Pharma but margins continue to bother along with one-off expenses due to the acquisition of stake in Aleor Dermaceuticals | Q4 FY22 Result & Earning Call Highlights